ArticleCell communication and signaling : CCS2026
ZNF33A activates Wnt/β-catenin signaling and promotes BCAA catabolism in colorectal cancer.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAberrant activation of Wnt/β-catenin signaling is a hallmark of colorectal cancer (CRC), but the upstream regulators and associated metabolic consequences remain incompletely defined. Branched-chain amino acid (BCAA) metabolism has been implicated in CRC progression, yet its regulation and functional role remain controversial. This study investigates the role of the transcription factor ZNF33A in CRC pathogenesis.
methodsZNF33A expression was examined in CRC tissues, cell lines, and public databases. Gain- and loss-of-function experiments were conducted in vitro (CCK8, EdU, soft agar, reporter assays, Co-IP, ChIP, BCAA assays) and in vivo (Lgr5-GFP mouse models and AOM/DSS-induced CRC). Statistical analyses included Student’s t-test, ANOVA, and Kaplan–Meier survival analysis.
resultsZNF33A was significantly upregulated in CRC tissues and correlated with poor prognosis. Overexpression of ZNF33A promoted proliferation, colony formation, and BCAA consumption, while its down-regulation suppressed tumor growth, stemness, and organoid formation. Mechanistically, ZNF33A bound β-catenin, enhanced β-catenin/TCF transcriptional activity, and induced expression of BCAT1, a key BCAA-catabolizing enzyme. Suppression of β-catenin or BCAT1 abrogated ZNF33A-driven oncogenic effects.
conclusionsZNF33A drives CRC progression by activating Wnt/β-catenin signaling and reprogramming BCAA metabolism via BCAT1. These findings identify ZNF33A as a potential therapeutic target and highlight BCAA metabolic modulation as a promising strategy for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.